MedPath

A comparative Clinical Study to evaluate the safety and efficacy of polyherbal formulation in high lipid level and overweight population.

Completed
Conditions
Overweight, (2) ICD-10 Condition: E789||Disorder of lipoprotein metabolism, unspecified,
Registration Number
CTRI/2016/01/006494
Lead Sponsor
Dabur India Limited
Brief Summary

Adult subjects of either sex with age between 18-65 years (both inclusive) will be screened for eligibility criteria.  Assessment of inclusion and exclusion criteria will be done based on clinical and laboratory investigations. Subject’s Prakruti evaluation will be done. If the subject meets the inclusion and exclusion criteria subject he/she will be randomized as per computer generated randomization list. Subject will be assigned to either of the three study groups. Subject will be asked to take the assigned study product in the respective dose for a period of 12 weeks. Subjects will be asked to follow up after every 3 weeks   At the end of the study, all subjects will undergo Laboratory investigations and ECG. Physician’s overall assessment of efficacy and safety will be done at the end of the study. Subject’s clinical examinations including vitals like Pulse, Respiration, Temperature and Blood Pressure  will be checked at baseline and thereafter every follow up visit. Adverse events will be recorded throughout the study.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
110
Inclusion Criteria
  • •Subjects of either sex (Male and Female) in the age group of 18 to 65 years, both inclusive.
  • •Subjects with LDL-C greater or equal than 130 at the time of screening.
  • •Subjects with BMI greater or equal than 25 •Subjects willing to follow the procedures as per the study protocol and voluntarily give written informed consent.
Exclusion Criteria
  • •Subjects with Diabetes Mellitus Type I and uncontrolled Diabetes Mellitus Type II •Subjects who have Diet with excess cholesterol, saturated fat or calories •Subjects with uncontrolled Hypothyroidism or Hyperthyroidism •Known cases of Severe/Chronic Hepatic or Renal disease •Known subject of any active malignancy.
  • •Subjects giving history of significant cardiovascular event < 12 weeks prior to randomization.
  • •Known case of Anorexia Nervosa or Bulimia nervosa •Chronic alcoholics / Alcohol Abuse •Subjects ECG demonstrating any signs of uncontrolled arrhythmia / acute ischemia.
  • •Subjects X- ray chest showing any active lesion of tuberculosis •Subjects having known chronic, contagious infectious disease, such as active tuberculosis Hepatitis B or C, or HIV.
  • •Subjects using any other investigational drug within 1 month prior to recruitment •Known hypersensitivity to any of the ingredients used in study drug •Pregnant and Lactating females.
  • •Subjects currently participating in any other Clinical study •Any other medical or surgical condition considered unsuitable for subject participation in the study as per Investigator’s judgment.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Change in LDL-C level at the end of study (12 weeks)12 weeks
2.Change in body weight at the end of study (12 weeks)12 weeks
Secondary Outcome Measures
NameTimeMethod
Change in LDL-C level at 6 weeks,Change in other lipid parameters such as Triglycerides (TG), Total Cholesterol (TC), High Density Lipoprotein (HDL), Body Weight, BMI, Waist circumference, Waist to hip ratio and EQ-5D Quality of Life (QOL) at 6 weeks and 12 weeks, Overall efficacy and safety of the study product as per the physician (CGI-I) at the end of study (12 weeks),Safety assessment by assessing adverse drug reactions, clinically significant abnormal laboratories values6 and 12 weeks

Trial Locations

Locations (4)

Department of Kayachikitsa, R A Podar Medical College (Ayu) & M.A. Podar Hospital

🇮🇳

Mumbai, MAHARASHTRA, India

Department of Kayachikitsa, Ayurved Seva Sangh

🇮🇳

Nashik, MAHARASHTRA, India

Department of Panchkarma

🇮🇳

Mumbai, MAHARASHTRA, India

Dept of Kayachikitsa, MAMS Sumatibhai Shah Ayurved Mahavidyalaya and Saneguruji Aarogya Kendra

🇮🇳

Pune, MAHARASHTRA, India

Department of Kayachikitsa, R A Podar Medical College (Ayu) & M.A. Podar Hospital
🇮🇳Mumbai, MAHARASHTRA, India
Dr Meenakshi Rewedkar Kole
Principal investigator
09757476325
minirewdkar@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.